Challenges to MG Clinical Trial Recruitment from a Tertiary Clinical Practice (S34.010)
To analyze the eligibility of acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ gMG) patients treated in routine care for phase III clinical trials.
Authors
- Srikanth Muppidi (ORCID: https://orcid.org/0000-0002-2773-2506)
- Neelam Goyal
- Katherine Clifford (ORCID: https://orcid.org/0000-0001-6969-4846)
- Nakul Katyal (ORCID: https://orcid.org/0000-0003-0249-1707)
- Martavius Lovall
- Angeline Ngo
Institutions
- University of Kentucky (US)
- Stanford Health Care (US)
- Mills Peninsula Health Services (US)
- Stanford University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211169
- Primary Topic
- Health and Medical Research Impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00